Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin

NCT02984982 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02984982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02984982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
November 15, 2016
Completion date
July 27, 2018
Enrollment
206 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, hypercholesterolemia